Literature DB >> 9626453

Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinoma: implications for prognosis.

H Porte1, J P Triboulet, L Kotelevets, F Carrat, S Prévot, B Nordlinger, Y DiGioia, A Wurtz, P Comoglio, C Gespach, E Chastre.   

Abstract

Molecular markers can improve staging and predict aggressive clinical behavior in esophageal cancer, thus helping to define appropriate therapeutic protocols and to identify patients who will benefit from surgery. We therefore characterized, by Northern blot and/or immunohistochemistry, the relative expression of three effectors involved in the invasion, angiogenesis, and dissemination of tumor cells in esophageal cancer versus nontumoral mucosae: (a) stromelysin-3 (ST3), a member of the metalloproteinase family; (b) basement membrane 40/secreted protein acidic and rich in cysteine (BM-40/SPARC), an extracellular matrix-associated protein involved in angiogenesis; and (c) the hepatocyte growth factor receptor MET, which triggers the scattering of epithelial cells. Results were analyzed in relation to clinicopathological parameters (cpTNE) including tumor size (T), lymph node status (N), periesophageal tissue invasion (E), disease recurrence, and overall survival. The ST3, BM-40/SPARC, and MET genes were found to be overexpressed in tumor samples compared to control mucosa. BM-40/SPARC and MET mRNA levels were not linked to any one of the cpTNE, indicating that this overexpression occurs at an early stage of neoplastic progression. In contrast, ST3 expression, identified by immunohistochemistry in fibroblastic cells surrounding neoplastic islets, correlated with tumor size and periesophageal tissue invasion. Of the 36 patients studied, those with high ST3 levels had shorter disease-free survival than those with low levels, but there was no relationship between the cpTNE and disease recurrence or survival. Our study demonstrates that ST3, BM-40/SPARC, and MET are involved in different steps of esophageal carcinogenesis and that ST3 overexpression is a marker of aggressive clinical behavior. We conclude that in esophageal cancer, ST3 might help to assess survival and the risk of recurrence after surgical resection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626453

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma.

Authors:  Mikiko Takikita; Nan Hu; Jian-Zhong Shou; Carol Giffen; Quan-Hong Wang; Chaoyu Wang; Stephen M Hewitt; Philip R Taylor
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

2.  High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines.

Authors:  Y Kato; F Frankenne; A Noël; N Sakai; Y Nagashima; S Koshika; K Miyazaki; J M Foidart
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Osteonectin influences growth and invasion of pancreatic cancer cells.

Authors:  Ahmed Guweidhi; Jörg Kleeff; Hassan Adwan; Nathalia A Giese; Moritz N Wente; Thomas Giese; Markus W Büchler; Martin R Berger; Helmut Friess
Journal:  Ann Surg       Date:  2005-08       Impact factor: 12.969

4.  SULF1 inhibits proliferation and invasion of esophageal squamous cell carcinoma cells by decreasing heparin-binding growth factor signaling.

Authors:  Chun-Tao Liu; Sheng-Tao Zhu; Peng Li; Yong-Jun Wang; Hao Zhang; Shu-Tian Zhang
Journal:  Dig Dis Sci       Date:  2012-10-05       Impact factor: 3.199

5.  In phyllodes tumors of the breast expression of SPARC (osteonectin/BM40) mRNA by in situ hybridization correlates with protein expression by immunohistochemistry and is associated with tumor progression.

Authors:  Nah Ihm Kim; Ga-Eon Kim; Ji Shin Lee; Min Ho Park
Journal:  Virchows Arch       Date:  2016-12-01       Impact factor: 4.064

6.  Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer.

Authors:  Irene Esposito; Hany Kayed; Shereen Keleg; Thomas Giese; E Helene Sage; Peter Schirmacher; Helmut Friess; Jörg Kleeff
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

7.  C. elegans as a model organism for in vivo screening in cancer: effects of human c-Met in lung cancer affect C. elegans vulva phenotypes.

Authors:  Shahid S Siddiqui; Sivakumar Loganathan; Soundararajan Krishnaswamy; Leonardo Faoro; Ramasamy Jagadeeswaran; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2008-03-05       Impact factor: 4.742

8.  cDNA array analysis of SPARC-modulated changes in glioma gene expression.

Authors:  William A Golembieski; Sandra A Rempel
Journal:  J Neurooncol       Date:  2002-12       Impact factor: 4.130

9.  Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis.

Authors:  Vinayak Nagaraja; Guy D Eslick
Journal:  J Gastrointest Oncol       Date:  2014-02

10.  SPARC: a matricellular regulator of tumorigenesis.

Authors:  Shanna A Arnold; Rolf A Brekken
Journal:  J Cell Commun Signal       Date:  2009-10-07       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.